Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Data Exclusivity Remains A Top Issue In U.S. Trade Representative's 2011 Special 301 Report

This article was originally published in PharmAsia News

Executive Summary

The failure of U.S. trading partners to adequately protect pharmaceutical test data remains one of the top concerns of the United States Trade Representative in its 2011 Special 301 Report on intellectual property rights

You may also be interested in...



Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels

While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has focused on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use that as a template for future free trade agreements.

Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels

While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has been on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use it as a template for future free trade agreements.

Forced Technology Transfer Hinders Innovation In China – USTR

China still has major intellectual property enforcement problems that unfairly disadvantage U.S. IP rights holders in the country.

Related Content

Latest News
UsernamePublicRestriction

Register

SC078121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel